Abstract
Dopamine receptors 1 and 2 (DRD1, DRD2) are essential for signaling in the brain for a multitude of brain functions. Previous work using several antibodies against these receptors is abundant but only the minority of antibodies used have been validated and, therefore, the results of these studies remain uncertain. Herein, antibodies against DRD1 (Merck Millipore AB1765P, Santa Cruz Biotechnology sc-14001, Sigma Aldrich D2944, Alomone Labs ADR-001) and DRD2 (Abcam ab21218, Merck Millipore AB5084P, Santa Cruz Biotechnology sc-5303) have been tested using western blotting and immunohistochemistry on mouse striatum (wild type and corresponding knock-out mice) and when specific, they were further evaluated on rat and human striatum. Moreover, a DRD1 antibody and a DRD2 antibody that were found specific in our tests were used for immunoprecipitation with subsequent mass spectrometrical identification of the immunoprecipitate. Two out of nine antibodies (anti DRD1 Sigma Aldrich D2944 and anti DRD2 Merck Millipore AB5084P) against the abovementioned dopamine receptors were specific for DRD1 and DRD2 as evaluated by western blotting and immunohistochemistry and the immunoprecipitate indeed contained DRD1 and DRD2 as revealed by mass spectrometry. The observed findings may question the use of so far non-validated antibodies against the abovementioned dopamine receptors. Own observations may be valuable for the interpretation of previous results and the design of future studies using dopamine receptors DRD1 or DRD2.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alcaro A, Huber R, Panksepp J (2007) Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Brain Res Rev 56(2):283–321. doi:10.1016/j.brainresrev.2007.07.014
Al-Khaled M, Heldmann M, Bolstorff I, Hagenah J, Munte TF (2015) Intertemporal choice in Parkinson’s disease and restless legs syndrome. Parkinsonism Relat Disord 21(11):1330–1335. doi:10.1016/j.parkreldis.2015.09.026
Barnes JJ, Dean AJ, Nandam LS, O’Connell RG, Bellgrove MA (2011) The molecular genetics of executive function: role of monoamine system genes. Biol Psychiatry 69(12):e127–e143. doi:10.1016/j.biopsych.2010.12.040
Bermak JC, Li M, Bullock C, Zhou QY (2001) Regulation of transport of the dopamine D1 receptor by a new membrane-associated ER protein. Nat Cell Biol 3(5):492–498. doi:10.1038/35074561
Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J, Anagnostou V, Rimm D (2010) Antibody validation. Biotechniques 48(3):197–209. doi:10.2144/000113382000113382
Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M (2014) Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteom 13(9):2513–2526. doi:10.1074/mcp.M113.031591
Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148(11):1474–1486. doi:10.1176/ajp.148.11.1474
Giros B, Sokoloff P, Martres MP, Riou JF, Emorine LJ, Schwartz JC (1989) Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 342(6252):923–926. doi:10.1038/342923a0
Hu Z, Oh EH, Chung YB, Hong JT, Oh KW (2015) Predominant D1 Receptors Involvement in the Over-expression of CART Peptides after Repeated Cocaine Administration. Korean J Physiol Pharmacol 19(2):89–97. doi:10.4196/kjpp.2015.19.2.89
Jaber M, Robinson SW, Missale C, Caron MG (1996) Dopamine receptors and brain function. Neuropharmacology 35(11):1503–1519
Jensen BC, Swigart PM, Simpson PC (2009) Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch Pharmacol 379(4):409–412. doi:10.1007/s00210-008-0368-6
Jositsch G, Papadakis T, Haberberger RV, Wolff M, Wess J, Kummer W (2009) Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 379(4):389–395. doi:10.1007/s00210-008-0365-9
Keiflin R, Janak PH (2015) dopamine prediction errors in reward learning and addiction: from theory to neural circuitry. Neuron 88(2):247–263. doi:10.1016/j.neuron.2015.08.037
Khan ZU, Mrzljak L, Gutierrez A, de la Calle A, Goldman-Rakic PS (1998) Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci USA 95(13):7731–7736
Levey AI, Hersch SM, Rye DB, Sunahara RK, Niznik HB, Kitt CA, Price DL, Maggio R, Brann MR, Ciliax BJ (1993) Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci USA 90(19):8861–8865
Monsma FJ Jr, McVittie LD, Gerfen CR, Mahan LC, Sibley DR (1989) Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 342(6252):926–929. doi:10.1038/342926a0
Nguyen CL, Tran AH, Matsumoto J, Hori E, Uwano T, Ono T, Nishijo H (2014) Hippocampal place cell responses to distal and proximal cue manipulations in dopamine D2 receptor-knockout mice. Brain Res 1567:13–27. doi:10.1016/j.brainres.2014.04.023
Olsen JV, de Godoy LM, Li G, Macek B, Mortensen P, Pesch R, Makarov A, Lange O, Horning S, Mann M (2005) Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteom MCP 4(12):2010–2021. doi:10.1074/mcp.T500030-MCP200
Puig MV, Rose J, Schmidt R, Freund N (2014) Dopamine modulation of learning and memory in the prefrontal cortex: insights from studies in primates, rodents, and birds. Front Neural Circuits 8:93. doi:10.3389/fncir.2014.00093
Schultz W (2002) Getting formal with dopamine and reward. Neuron 36(2):241–263
Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M, Cox J (2016) The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 13(9):731–740. doi:10.1038/nmeth.3901
Uhlen M, Bandrowski A, Carr S, Edwards A, Ellenberg J, Lundberg E, Rimm DL, Rodriguez H, Hiltke T, Snyder M, Yamamoto T (2016) A proposal for validation of antibodies. Nat Methods 13(10):823–827. doi:10.1038/nmeth.3995nmeth.3995
Wisniewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample preparation method for proteome analysis. Nat Methods 6(5):359–362. doi:10.1038/nmeth.1322
Yamaguchi H, Aiba A, Nakamura K, Nakao K, Sakagami H, Goto K, Kondo H, Katsuki M (1996) Dopamine D2 receptor plays a critical role in cell proliferation and proopiomelanocortin expression in the pituitary. Genes Cells 1(2):253–268
Zhang L, McCarthy DM, Sharma N, Bhide PG (2015) Dopamine receptor and Galpha(olf) expression in DYT1 dystonia mouse models during postnatal development. PLoS One 10(4):e0123104. doi:10.1371/journal.pone.0123104
Acknowledgements
We are highly indebted to Prof. Tibor Harkany for supporting the study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Stojanovic, T., Orlova, M., Sialana, F.J. et al. Validation of dopamine receptor DRD1 and DRD2 antibodies using receptor deficient mice. Amino Acids 49, 1101–1109 (2017). https://doi.org/10.1007/s00726-017-2408-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-017-2408-3